Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorkit ASP 75 is a fixed-dose combination generic medication containing atorvastatin and aspirin (acetylsalicylic acid). Atorvastatin is a lipid-lowering agent that acts as a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), preventing the synthesis of thromboxane A2 and subsequent platelet aggregation. This combination is used for the secondary prevention of cardiovascular events in patients with established atherosclerotic cardiovascular disease, addressing both dyslipidemia and thrombotic risk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + aspirin.